Fondaparinux

Revision as of 22:42, 9 October 2016 by ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Anticoagulant *Dosage Forms: *Routes of Administration: Subcutaneous, IV *Common Trade Names: Arixtra ==Adult Dosing== *STEMI, NSTEMI: 2.5mg daily *...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type: Anticoagulant
  • Dosage Forms:
  • Routes of Administration: Subcutaneous, IV
  • Common Trade Names: Arixtra

Adult Dosing

  • STEMI, NSTEMI: 2.5mg daily
  • Acute DVT, PE: 5-10mg subq daily until warfarin therapeutic
  • VTE prophylaxis: 2.5mg subq daily

Pediatric Dosing

Safety/efficacy not established

Special Populations

  • Pregnancy Rating: B
  • Lactation risk: Infant risk cannot be ruled out
  • Renal dosing: contraindicated if CrCl <30, use with caution if CrCl 30-50
  • Hepatic dosing: no adjustment

Contraindications

  • Allergy to class/drug
  • Active major bleeding
  • Bacterial endocarditis
  • Thrombocytopenia associated with antiplatelet antibody when tested with fondaparinux
  • Weight <50kg
  • Severe renal impairment (CrCl <30)

Adverse Reactions

Serious

  • Bleeding, anemia, thrombocytopenia
  • Epidural hematoma, spinal subdural hematoma

Common

  • Injection site reaction, rash
  • Fever

Pharmacology

  • Half-life: 17-21h
  • Metabolism:
  • Excretion: Renal

Mechanism of Action

  • Inhibits antithrombin III, neutralizing Factor Xa (similar to low molecular weight heparins)

Comments

See Also

References

Authors:

Claire